# Arcus Biosciences, Inc. clinical trials: 32 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 32 trials with Arcus Biosciences, Inc. as lead sponsor, 4 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Arcus Biosciences, Inc.: 32 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/arcus-biosciences-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 32
- Recruiting or not yet: 4
- Read on: November 19, 2026

## Trials

The 25 newest of 32, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 7, 2026 | NCT07751250 | Comparative PK Assessment Study of Casdatifan in Moderate Hepatically Impaired Participants Versus Matched Participants With Normal Hepatic... | Arcus Biosciences, Inc. | Phase 1 | Recruiting | Healthy Participants, Hepatic Impairment | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07751250) |
| June 23, 2026 | NCT07662057 | A Study to Investigate the Safety, Tolerability, and PK of AB102 in Healthy Participants | Arcus Biosciences, Inc. | Phase 1 | Recruiting | Healthy Volunteers | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07662057) |
| June 11, 2026 | NCT07641881 | A Bioequivalence Study Between Two Casdatifan Tablet Strengths and Food Effect Study of Casdatifan in Healthy Adult Participants | Arcus Biosciences, Inc. | Phase 1 | Completed | Healthy Participants | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07641881) |
| January 23, 2026 | NCT07364214 | Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24) | Arcus Biosciences, Inc. | Phase 1 | Completed | Healthy Participants | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07364214) |
| June 10, 2025 | NCT07011719 | Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma | Arcus Biosciences, Inc. | Phase 3 | Recruiting | Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma | 720 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07011719) |
| April 9, 2025 | NCT06919991 | Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29) | Arcus Biosciences, Inc. | Phase 1 | Completed | Healthy Participants | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06919991) |
| September 23, 2024 | NCT06608927 | Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma | Arcus Biosciences, Inc. | Phase 3 | Active not recruiting | Metastatic Pancreatic Ductal Adenocarcinoma | 610 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06608927) |
| November 7, 2023 | NCT06120075 | A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies | Arcus Biosciences, Inc. | Phase 1 | Completed | Advanced Cancer | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06120075) |
| August 22, 2023 | NCT06004921 | A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AB801 in Healthy Volunteers | Arcus Biosciences, Inc. | Phase 1 | Completed | Cancer | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06004921) |
| August 21, 2023 | NCT05999513 | A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult Volunteers | Arcus Biosciences, Inc. | Phase 1 | Completed | Healthy Participants | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05999513) |
| June 6, 2023 | NCT05891171 | Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers | Arcus Biosciences, Inc. | Phase 1 | Active not recruiting | Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05891171) |
| October 5, 2022 | NCT05568095 | A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper... | Arcus Biosciences, Inc. | Phase 3 | Completed | Advanced Upper Gastrointestinal Tract Adenocarcinoma | 1,040 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05568095) |
| September 10, 2022 | NCT05536141 | A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors | Arcus Biosciences, Inc. | Phase 1 | Recruiting | Clear Cell Renal Cell Carcinoma, Solid Tumors | 512 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05536141) |
| June 9, 2022 | NCT05411146 | A Study Investigating the Safety, Absorption, and Elimination of Radioactively Labeled Etrumadenant, a New Compound in the Treatment of... | Arcus Biosciences, Inc. | Phase 1 | Completed | Healthy Participants | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05411146) |
| April 15, 2022 | NCT05329766 | A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper... | Arcus Biosciences, Inc. | Phase 2 | Completed | Gastrointestinal Tract Malignancies | 332 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05329766) |
| March 14, 2022 | NCT05277012 | A Study to Evaluate Pharmacokinetics (PK) of Etrumadenant Tablet and Capsule Formulations in Healthy Adult Participants | Arcus Biosciences, Inc. | Phase 1 | Completed | Healthy Participants | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05277012) |
| December 10, 2021 | NCT05154136 | A Drug-Drug Interaction Study to Evaluate the Effect of Itraconazole on the Pharmacokinetic Profile of Etrumadenant in Healthy Adult... | Arcus Biosciences, Inc. | Phase 1 | Completed | Healthy Participants | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05154136) |
| November 11, 2021 | NCT05117554 | Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile With Oral AB521 in Healthy Volunteers | Arcus Biosciences, Inc. | Phase 1 | Completed | Healthy Participants | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05117554) |
| February 26, 2021 | NCT04772989 | A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies | Arcus Biosciences, Inc. | Phase 1 | Completed | Advanced Solid Tumor, Non Small Cell Lung Cancer (NSCLC), Melanoma, Cervical Cancer, Multiple Myeloma, Lymphoma... | 94 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04772989) |
| February 3, 2021 | NCT04736173 | Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer | Arcus Biosciences, Inc. | Phase 2 | Completed | Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer | 169 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04736173) |
| December 9, 2020 | NCT04660812 | An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic... | Arcus Biosciences, Inc. | Phase 1/2 | Completed | Metastatic Colorectal Cancer | 227 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04660812) |
| October 5, 2020 | NCT04575311 | A Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers | Arcus Biosciences, Inc. | Phase 1 | Completed | Healthy Volunteers | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04575311) |
| May 11, 2020 | NCT04381832 | Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer | Arcus Biosciences, Inc. | Phase 1/2 | Completed | Prostatic Neoplasms, Castration-Resistant, Androgen-Resistant Prostatic Neoplasms, Castration Resistant Prostatic... | 173 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04381832) |
| February 10, 2020 | NCT04262856 | Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer | Arcus Biosciences, Inc. | Phase 2 | Completed | Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer | 151 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04262856) |
| September 26, 2019 | NCT04104672 | A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies | Arcus Biosciences, Inc. | Phase 1 | Completed | Advanced Pancreatic Cancer | 196 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04104672) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 24 |
| Phase 1/2 | 2 |
| Phase 2 | 3 |
| Phase 3 | 3 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 26 |
| Recruiting | 4 |
| Active not recruiting | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Non-Small-Cell Lung | 7 |
| Stomach Neoplasms | 4 |
| Carcinoma, Renal Cell | 3 |
| Colorectal Neoplasms | 3 |
| Ovarian Neoplasms | 3 |
| Kidney Neoplasms | 2 |
| Pancreatic Neoplasms | 2 |
| Melanoma | 2 |
| Uterine Cervical Neoplasms | 2 |
| Esophageal Neoplasms | 2 |
| Squamous Cell Carcinoma of Head and Neck | 2 |
| Urinary Bladder Neoplasms | 2 |
| Adenocarcinoma Of Esophagus | 2 |
| Triple Negative Breast Neoplasms | 2 |
| Lung Neoplasms | 2 |
| Clear-cell metastatic renal cell carcinoma | 1 |
| Erythrocytosis, Familial, 4 | 1 |
| Multiple Myeloma | 1 |
| Lymphoma, Non-Hodgkin | 1 |
| Lymphoma, Large B-Cell, Diffuse | 1 |
| Breast Neoplasms | 1 |
| Endometrial Neoplasms | 1 |
| Carcinoma, Merkel Cell | 1 |
| Prostatic Neoplasms, Castration-Resistant | 1 |
| Neoplasms | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Excavation contractors in the United States](https://specstream.ai/data/businesses/excavation-contractors/united-states)
- [Business law firms in the United States](https://specstream.ai/data/businesses/business-law-firms/united-states)
- [West African restaurants in the United States](https://specstream.ai/data/businesses/west-african-restaurants/united-states)
- [Restaurant wholesale companies in the United States](https://specstream.ai/data/businesses/restaurant-wholesale-companies/united-states)
- [Medical testing laboratories in the United States](https://specstream.ai/data/businesses/medical-testing-laboratories/united-states)
- [General hospitals in the United States](https://specstream.ai/data/businesses/general-hospitals/united-states)
